Owlet, Inc.
HealthcareNYSE:OWLT · New York Stock Exchange
+$0.06 today
Vol 0.11M · Avg 0.25M
Management
Put operating results in leadership context
Review returns on capital, executive background, insider transactions, and growth quality to judge whether management is compounding value well.
Return Metrics
ROE, ROIC & ROA over time
ROE
-112.1%
avg 127.4%
ROIC
-15.9%
avg -221.7%
ROA
-46.4%
avg -60.5%
Analysis
ROIC is currently the strongest return metric at -15.9% versus its period average of -221.7%. 0 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.
Management
Key executives, compensation & ownership
| Name | Title | Compensation | Tenure | Age | Shares Owned | Ownership % |
|---|---|---|---|---|---|---|
Kurt Workman | Co-Founder, President, CEO & Director | $799,405.00 | — | 36 | $1.23M | 6.81% |
Amanda Twede Crawford | Chief Financial Officer | $513,735.00 | — | 38 | $159,679.00 | 0.88% |
David Kizer | Chief Operating Officer | — | — | — | — | — |
Burc Sahinoglu | Chief Technology Officer | — | — | — | — | — |
Jennifer Billington | Chief Revenue Officer | — | — | — | — | — |
Elizabeth Teran | Chief Parent Officer | — | — | — | — | — |
Jay Gentzkow | Vice President of Investor Relations | — | — | — | — | — |
Insider Trading
SEC Form 4 transactions — last 12 months
Buys
0
$0.00
Sells
15
$851,748.63
Net Sentiment
$851,748.63
Net selling
Most Active
Harris Jonathan
7 transactions
1–10 of 15
Analysis
Insiders reported 0 buys worth $0.00 and 15 sells worth $851,748.63 over the last 12 months. That adds up to net selling of $851,748.63. Harris Jonathan was the most active insider with 7 transactions.
Growth Analysis
Historical CAGR & forward analyst estimates
| Metric | 10yr | 5yr | 3yr | Fwd Est. |
|---|---|---|---|---|
| EPS | N/A | N/A | N/A | N/A1 analysts |
| Revenue | N/A | N/A | -10.5% | +31.3% (6yr)1 analysts |
| Net Income | N/A | N/A | N/A | N/A1 analysts |
| EBIT | N/A | N/A | N/A | N/A1 analysts |
Analysis
Recent growth has been strongest in Revenue at -10.5% over three years. Forward estimates point to Revenue at +31.3% (6yr), giving you a quick check on whether expectations are accelerating or cooling.
Competitors
Peer companies in the same sector
Anteris Technologies Global Corp.
NASDAQ:AVR
$336.61M
Elicio Therapeutics, Inc.
NASDAQ:ELTX
$283.43M
Anika Therapeutics, Inc.
NASDAQ:ANIK
$195.86M
MaxCyte, Inc.
NASDAQ:MXCT
$119.98M
Cardiff Oncology, Inc.
NASDAQ:CRDF
$105.29M
Corbus Pharmaceuticals Holdings, Inc.
NASDAQ:CRBP
$102.67M
Lucid Diagnostics Inc.
NASDAQ:LUCD
$98.28M
Rapid Micro Biosystems, Inc.
NASDAQ:RPID
$79.77M
LENSAR, Inc.
NASDAQ:LNSR
$70.45M
Applied Therapeutics, Inc.
APLT
$14.86M
Who manages OWLT?
Owlet, Inc. (OWLT) lists 7 active executives. The top listed executive is David Kizer, Chief Operating Officer.
Are OWLT insiders buying or selling?
Recent insider activity shows net buying of $116.76M.
Explore More
Continue the stock analysis
Jump to another research area for this company.